As companies strive to make their sequencing capabilities longer, more accurate, faster, and cheaper, the detection of low frequency DNA mutations remains one limitation that no one has overcome. The young start-up, TwinStrand Biosciences, a spin out of the University of Washington, is hoping to crack that nut with their duplex sequencing technology.
Duplex sequencing improves sequencing accuracy to a very high degree, making it possible to detect low frequency variants such as one cancer cell among 10,000 normal cells or ultra-rare mutations caused by carcinogens, aging, and the earliest stages of cancer.
To do this, the . . .